ATRX - Adhera Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0400
-0.0050 (-11.11%)
At close: 1:32PM EST
Stock chart is not supported by your current browser
Previous Close0.0450
Open0.0400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0400 - 0.0450
52 Week Range0.0400 - 0.5500
Volume3,224
Avg. Volume20,426
Market Cap434,780
Beta (3Y Monthly)2.33
PE Ratio (TTM)N/A
EPS (TTM)-1.1470
Earnings DateNov 18, 2019 - Nov 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Adhera Therapeutics Announces Third Quarter 2019 Financial Results and Operational Highlights

    RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / November 14, 2019 / Adhera Therapeutics, Inc. (ATRX), an emerging specialty pharmaceutical company that commercializes and delivers effective, patient-centric treatment in chronic care, to improve and simplify the quality of care for patients suffering from chronic diseases, reported financial and operating results for the third quarter of 2019 today. During the third quarter the Company achieved three important milestones in progressing its ‘invest to grow' strategy and removing barriers to performance, by scaling up 1) its marketing capabilities, 2) its distribution capabilities and 3) its product portfolio. Marketing - The Company entered into a strategic partnership with Indegene Inc. to deploy Indegene's proprietary co-commercialization model to expand commercialization for the Company's primary product, Prestalia®, across the United States.

  • GlobeNewswire

    Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock

    Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced offer to exchange all of the outstanding shares of the Series E Convertible Preferred Stock and Series F Convertible Preferred Stock of the Company. As per the terms of the offer, the Company offered, in exchange for each share of preferred stock tendered, such number of shares of the common stock of the Company as is equal to the quotient obtained by dividing (A) the “stated value” of such tendered share of preferred stock by (B) $0.50 (subject to an adjustment mechanism described in the Schedule TO).

  • ACCESSWIRE

    Adhera Therapeutics and Indegene Announce Next Gen Commercialization Partnership

    RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 10, 2019 / Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into a partnership with Indegene Inc. to deploy the proprietary Indegene co-commercialization model to expand commercialization for its drug, PRESTALIA®, across the United States. PRESTALIA® (https://PRESTALIA-us.net/package-insert) combines two key hypertensive agents, perindopril arginine and amlodipine besylate, and is indicated for the treatment of hypertension.

  • ACCESSWIRE

    Adhera and Allegis Pharma Announce Co-Promotion Agreement

    RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 6, 2019 / Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into an agreement with Allegis Pharmaceuticals, LLC to co-promote Allegis’ Nitrolingual® Pumpspray, a nitroglycerin lingual spray, indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. Nitroglycerin is listed as one of the top 300 most prescribed drugs with approximately 3.4 million annual prescriptions in 2016 (https://clincalc.com/DrugStats/Top300Drugs.aspx).

  • GlobeNewswire

    Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer

    Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that its Board of Directors has appointed Nancy R. Phelan to serve as Chief Executive Officer of the Company. Ms. Phelan has served as a member of the Board of Directors since October 2018. “I am excited to assume the role of Chief Executive Officer of Adhera Therapeutics,” Ms. Phelan said.

  • ACCESSWIRE

    Adhera Therapeutics' DyrctAxessTM Platform Helps 78% of Patients Adhere to PRESTALIA(R); Achieves Exceptionally High Level of Drug Adherence to an Antihypertensive Medication

    Over 200 prescribers have written at least one prescription for PRESTALIA and over 600 patients are taking the medication PRESTALIA was launched in Q3 2018, powered by the Company's proprietary DyrctAxess ...